BackZhejiang East Asia Pharmaceutical , Ltd. Overview

Zhejiang East Asia Pharmaceutical , Ltd. Current Assets

Zhejiang East Asia Pharmaceutical , Ltd.'s current assets is $980M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$976.39M
↓ 33.23% YoYΔ $-486.01M vs prior year quarter

Peer trimmed avg / median

Loading

Zhejiang East Asia Pharmaceutical , Ltd. Current Assets History

Loading

Zhejiang East Asia Pharmaceutical , Ltd. vs. peers: Current Assets Comparison

Loading

Zhejiang East Asia Pharmaceutical , Ltd. Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Zhejiang East Asia Pharmaceutical , Ltd. (605177.SS) FAQ

Zhejiang East Asia Pharmaceutical , Ltd.'s current assets stands at $980M as of June 2026. That compares with $1.5B in the prior-year period — down 33.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Zhejiang East Asia Pharmaceutical , Ltd. reported $980M in current assets versus $1.5B a year earlier — a 33.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $1.5B in the prior-year period — down 33.2% year over year. Sustained growth in current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Zhejiang East Asia Pharmaceutical , Ltd.'s current assets evolved across reporting periods, while the comparison chart places 605177.SS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current assets is commonly used to spot outliers. Zhejiang East Asia Pharmaceutical , Ltd.'s reading of $980M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.